ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 36980705

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety.

Swan D and 3 others. Cancers (Basel), 2023. Cited by 34 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety. Papers, record 36980705. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36980705

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
34
iCite
Relative citation ratio, by iCite
2.84
iCite
Revised in PubMed
2023-03-31
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Swan DDawnhttps://orcid.org/0000-0003-1374-7333
2Murphy PPhilip
3Glavey SSiobhan
4Quinn JJohn

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References74

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112,528,874Review of 1027 patients with newly diagnosed multiple myeloma.Mayo Clin Proc2003https://conductscience.org/library/papers/12528874PubMed
235,661,166Teclistamab in Relapsed or Refractory Multiple Myeloma.N Engl J Med2022https://conductscience.org/library/papers/35661166PubMed
324,036,947Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance.Blood Cancer J2013https://conductscience.org/library/papers/24036947PubMed
426,692,321Bispecific antibodies and their applications.J Hematol Oncol2015https://conductscience.org/library/papers/26692321PubMed
529,998,217Bispecific antibodies in cancer immunotherapy.Ther Adv Vaccines Immunother2018https://conductscience.org/library/papers/29998217PubMed
636,507,686Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.N Engl J Med2022https://conductscience.org/library/papers/36507686PubMed
734,472,091The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies.Br J Haematol2022https://conductscience.org/library/papers/34472091PubMed
826,240,224Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.J Clin Oncol2015https://conductscience.org/library/papers/26240224PubMed
910,903,733
TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase.
J Immunol2000https://conductscience.org/library/papers/10903733PubMed
1036,857,755Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.Blood Adv2023https://conductscience.org/library/papers/36857755PubMed

1 to 10 of 74

See all 74 references

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.

PMIDTitleJournalYearIn PapersSource
42,454,131Practical recommendations for infectious prophylaxis and vaccination in multiple myeloma patients.Front Med (Lausanne)2026https://conductscience.org/library/papers/42454131PubMed
42,200,829
Sociodemographic, Clinical, and Therapeutic Characterization of Multiple Myeloma Patients (CharisMMa Study) with Symptomatic Relapse and/or Refractory Disease: An Observational, Multicenter Study in Portugal.
Hematol Rep2026https://conductscience.org/library/papers/42200829PubMed
42,012,573Clinical Benefit of Multiple Myeloma Drugs at Regulatory Approval in Brazil, Europe, and the USA: A Retrospective Cohort Study (2003-2024).Clin Drug Investig2026https://conductscience.org/library/papers/42012573PubMed
41,758,268Bispecific and multispecific immune engagers for redirecting innate and adaptive immunity against hematologic cancers.Discov Oncol2026https://conductscience.org/library/papers/41758268PubMed
41,432,547Establishing Barriers to and Enablers of Nurse-Enabled Subcutaneous Therapy Self-Administration Programs for Patients With Myeloma: Protocol for a Qualitative Descriptive Study.JMIR Res Protoc2025https://conductscience.org/library/papers/41432547PubMed
40,940,825Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials.Cancers (Basel)2025https://conductscience.org/library/papers/40940825PubMed
40,890,126Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma.NPJ Syst Biol Appl2025https://conductscience.org/library/papers/40890126PubMed
40,022,009Treatment patterns and clinical outcomes for multiple myeloma in Korean patients: a database study.BMC Cancer2025https://conductscience.org/library/papers/40022009PubMed
39,988,462Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma.Eur J Haematol2025https://conductscience.org/library/papers/39988462PubMed
39,939,863Construction of tetravalent bispecific Tandab (CD3/BCMA)-secreting human umbilical cord mesenchymal stem cells and its efficiency in the treatment of multiple myeloma.Stem Cell Res Ther2025https://conductscience.org/library/papers/39939863PubMed

1 to 10 of 23

See all 23 cited by

Genes19

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD19930PubTator's text mininghttps://conductscience.org/library/genes/930NCBI Gene
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD38952PubTator's text mininghttps://conductscience.org/library/genes/952NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CD47961PubTator's text mininghttps://conductscience.org/library/genes/961NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
CDCA855,143PubTator's text mininghttps://conductscience.org/library/genes/55143NCBI Gene
CXADRP1653,108PubTator's text mininghttps://conductscience.org/library/genes/653108NCBI Gene
CXCR610,663PubTator's text mininghttps://conductscience.org/library/genes/10663NCBI Gene
FCRL583,416PubTator's text mininghttps://conductscience.org/library/genes/83416NCBI Gene

1 to 10 of 19

See all 19 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36980705

GET https://conductscience.org/api/papers/v1/36980705/references?page=2

API referenceFor AI assistants